- The 2020 Spring CMTA Report
In a world turned upside down, The CMTA Report continues to bring you help for today and hope for tomorrow. In this issue you’ll find helpful stories on tendon transfers, HNPP and nerve conduction studies, as well as hopeful news ...Read more ... - CMTA Board Approves CMT1B ProjectThe CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.Read more ...
- Coronavirus (COVID-19) and CMTThe CMTA is aware that the coronavirus (COVID-19) may have more of an impact on people and families who are at higher risk of infection, so we are reaching out to share resources and ensure you are informed.Read more ...
- CMTA Event Schedule Update from CEO Amy GrayThe CMTA has decided to postpone and/or reschedule all upcoming CMTA branch meetings, events and walks originally scheduled to occur in March through May of 2020.Read more ...
- Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth DiseaseACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.Read more ...
When you participate in the Walk 4 CMT campaign, you fund patient programs and treatment research initiatives to better the lives of the the 3 million people living with CMT.
By investing in the CMTA’s Legacy Society, you can ensure that children with CMT will grow up with the hope of a world without CMT.
